Surgery alone has long been the standard treatment for patients with operable non–small-
cell lung cancer (NSCLC). However, despite complete resection, 5-year survival rates have …

Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with
patients having a poor prognosis. Approximately one third of NSCLC patients present with …

Background On the basis of a previous meta-analysis, the International Adjuvant Lung
Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy …

Following the 1995 meta-analysis on the role of postoperative chemotherapy in NSCLC,
many randomized controlled trials (RCTs) have evaluated the effect of adjuvant cisplatin …

Despite surgical resection, patients with early-stage (I to IIIA) non–small cell lung cancer
(NSCLC) are at considerable risk of recurrence and death from their lung cancer. In recent …

Surgery is regarded as the primary treatment modality for early stage non-small cell lung
cancer (NSCLC), but even after complete resection, a substantial percentage of these …

Abstract The recently reported International Adjuvant Lung Cancer Trial (IALT) was
designed to assess the potential benefit of three to four cycles of adjuvant cisplatin-based …

Despite improved surgical techniques, relapse and mortality rates remain high among
patients with resected non-small cell lung cancer. Numerous randomized controlled trials in …

Purpose Based on 5-year or shorter-term follow-up data in recent randomized trials,
adjuvant cisplatin-based chemotherapy is now generally recommended after complete …

7507 Background: Based on 4 to 5-year follow-up data in recent randomized trials, adjuvant
cisplatin-based chemotherapy is now generally recommended after complete surgical …